1. Introduction {#sec1}
===============

Cerebrospinal fluid (CSF) biomarkers, amyloid β~1--42~ (Aβ~1--42~), total tau (T-tau), and phosphorylated tau~181~ (P-tau), support the diagnosis of Alzheimer\'s disease (AD) [@bib1]. Unfortunately, susceptibility to preanalytical/analytical variation has hampered clinical implementation [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9]. The effect of long-term storage on CSF biomarkers is relevant because historical cohorts are needed to establish universal cutoff values. Evaporation during biobank storage is not an issue [@bib10], [@bib11], but the long-term stability of biomarkers has been poorly studied. The first study on this topic monitored Aβ~1--42~ and T-tau for 22 days and extrapolated these results using Arrhenius equations showing long-term stability at −80°C [@bib12]. Next, a study reported on a repetitive measurement of a quality control CSF sample for more than 2 years, resulting in stable Aβ~1--42~ concentrations [@bib13]. Another study compared aliquots of clinical samples for more than 0 to 6 years and reported stable Aβ~1--42~ and T-tau concentrations [@bib14]. In both the latter studies, however, analysis was done in different assay batches, which could have interfered with the potential effects of long-term storage.

We studied the levels of CSF biomarkers, Aβ~1--42~, T-tau, and P-tau, in relation to storage duration, starting from the assumption that mean biomarker levels of the average AD patient will not change over time. Similar collection procedures and assay batches thus precluded any preanalytical bias other than the length of biobank storage.

2. Methods {#sec2}
==========

2.1. Sample collection {#sec2.1}
----------------------

Patients underwent a standard clinical assessment and were diagnosed as probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer\'s Disease and Related Disorders Association (NINCDS-ADRDA) criteria [@bib15]. We assumed that the average biomarker concentrations in AD patients within a narrow age range and equal apolipoprotein E (*APOE*) genotype and gender distribution on a group level will remain similar, regardless of the inclusion year. CSF was collected by lumbar puncture in 10 mL polypropylene tubes (Sarstedt, Nümbrecht, Germany). CSF samples were centrifuged at 1800 to 2100*g* for 10 minutes at 4°C within 2 hours and a small amount, 0.35 to 2.5 mL, was transferred to 5 mL polypropylene tubes (Sarstedt) and used for routine analysis and biomarker measurement (Innotest β-AMYLOID (1--42), hTAU-Ag, and PHOSPHO-TAU (181p); Innogenetics, Belgium). The remaining CSF was divided into polypropylene tubes (1.5 or 2.0 mL; Sarstedt) in 0.5 mL volumes and stored in the biobank at −80°C [@bib16]. The protocol was approved by the institutional review board and subjects gave written consent.

2.2. Cohort selection {#sec2.2}
---------------------

We selected 148 patients diagnosed with probable AD included between September 2001 and October 2013: aged 64 to 72 years, MMSE score from 14 to 27, *APOE* genotypes ε3/ε3 (*n* = 41), ε3/ε4 (*n* = 69), and ε4/ε4 (*n* = 38), and a gender distribution of 78 females and 70 males. We aimed for an equally scattered distribution of these clinical characteristics of the samples over the inclusion years. The biobank collection protocol remained unchanged during this period, apart from a small change as follows: from 2008 to 2011 biobank vials of 0.5 mL (Brand, ref. 211-3211) were used.

2.3. Enzyme-linked immunosorbent assays {#sec2.3}
---------------------------------------

We determined Aβ~1--42~, T-tau, and P-tau concentrations in fresh biobank aliquots using one batch of sandwich Enzyme-linked immunosorbent assays (Innotest β-AMYLOID (1--42), Innotest hTAU-Ag, and Innotest PHOSPHO-TAU (181p); Fujirebio, Ghent, Belgium, former Innogenetics) between November 2015 and February 2016.

2.4. Statistical analysis {#sec2.4}
-------------------------

Linear regression analyses were performed to assess the effect of storage time in days on (1) biomarker levels (all reassessed in one batch) and (2) differences between new and old biomarker measurements. "β" expresses the slope of the linear regressions in picograms per milliliter per day ± standard error of the mean (SEM). To compare the remeasured values with the old values, Spearman correlation and Passing-Bablok regression were performed. *P* value \<.05 was considered significant. Analyses were done in R version 3.3.1.

3. Results {#sec3}
==========

3.1. Levels of CSF biomarkers Aβ~1--42~, T-tau, and P-tau are not related to storage time at −80°C {#sec3.1}
--------------------------------------------------------------------------------------------------

Biomarker values (median + range) were 516 (287--1314) pg/mL for Aβ~1--42~, 769 (112--2856) pg/mL for T-tau, and 83 (22--224) pg/mL for P-tau; these values were not part of the selection criteria. Linear regression analysis showed that there was no relation between storage time and biomarker value (β\[slope ± SEM\] = 0.015 ± 0.012 pg/mL per day for Aβ~1--42~, β = 0.048 ± 0.031 pg/mL per day for T-tau, and β = 0.0016 ± 0.0025 pg/mL per day for P-tau, all *P* \> .05) ([Fig. 1](#fig1){ref-type="fig"}). Confidence intervals (95%; CIs) of the linear regression model fit show that the yearly concentration changes for Aβ~1--42~, T-tau, and P-tau were between −3.2 and 14.2, −4.7 and 39.7, and between −1.2 and 2.4 pg/mL, respectively.Fig. 1CSF biomarker (A) Aβ~1--42~, (B) T-tau, and (C) P-tau concentrations over storage years at −80°C. Aβ~1--42~, T-tau, and P-tau concentrations were measured in biobanked samples of a homogenous AD patient cohort (*n* = 148) in a single assay batch. Linear regression analyses showed no significant effects of storage time on biomarker concentrations. Solid lines represent regression fit and dotted lines represent the 95% confidence intervals of the regression models. Abbreviations: Aβ~1--42,~ amyloid β~1--42~; AD, Alzheimer\'s disease; CSF, cerebrospinal fluid; n.s., not significant; T-tau, total tau; P-tau, phosphorylated tau~181~.

3.2. Comparison of old and new biomarker measurements {#sec3.2}
-----------------------------------------------------

We compared the remeasured Aβ~1--42~, T-tau, and P-tau concentrations with those measured at the time of inclusion in the biobank, showing strong correlations: ρ = 0.725 for Aβ~1--42~, ρ = 0.922 for T-tau, and ρ = 0.903 for P-tau ([Fig. 2](#fig2){ref-type="fig"}A--C). However, Passing-Bablok regression analyses showed systematic differences, indicated by the intercept of regression line, for Aβ~1--42~ (intercept = −98.0 \[95% CI = −171 to −24.0\], β = 1.09 \[95% CI = 0.92--1.24\]), proportional differences, indicated by the slope of the regression line, for T-tau (intercept = −4.06 \[95% = −28.9 to 22.5\], β = 0.83 \[95% CI = 0.79--0.89\]) but no difference for P-tau levels (intercept = −5.91 \[95% CI = −11.6 to 0.00\], β = 1.09 \[95% CI = 1.00--1.17\]) ([Fig. 2](#fig2){ref-type="fig"}A--C).Fig. 2Comparison of remeasured biomarker values with biomarker values at the time of biobank inclusion. Passing-Bablok regression fit and Spearman\'s correlation of old and new values showing a systematic difference for Aβ~1--42~ (A), a proportional difference for T-tau (B), and no difference for P-tau (C). Differences in new and old Aβ~1--42~, T-tau, and P-tau concentrations in relation to storage time are given in (D), (E), and (F), respectively. For Aβ~1--42~ (D) and T-tau (E), differences between new and old concentrations increased with longer storage times. Gray areas indicate the 95% confidence interval of the regression fit. Abbreviations: Aβ~1--42,~ amyloid β~1--42~; AD, Alzheimer\'s disease; CSF, cerebrospinal fluid; T-tau, total tau; P-tau, phosphorylated tau~181~.

3.3. Differences between new and old values is related to batch changes {#sec3.3}
-----------------------------------------------------------------------

Differences between new and old measurements of Aβ~1--42~ were strongly related to storage time (β ± SEM = 0.046 ± 0.0062 pg/mL per day; *P* \< .001) ([Fig. 2](#fig2){ref-type="fig"}D), where the more recent measurements were consistently higher. For T-tau, a similar trend was observed (β ± SEM = 0.031 ± 0.011 pg/mL per day; *P* \< .01) ([Fig. 2](#fig2){ref-type="fig"}E), although not as strong as for Aβ~1--42~. For P-tau, no trend was observed (β ± SEM = 0.00023 ± 0.0011 pg/mL per day, *n*.*s*.) ([Fig. 2](#fig2){ref-type="fig"}F).

From 2004 to 2015, 30 batches of Aβ~1--42~ kits were sequentially used in our laboratory. Before 2004, biomarker measurements were too infrequent to consider batch shifts. Internal quality control samples, measured over the years, confirmed that there was an upward drift in Aβ~1--42~ concentrations (data not shown) [@bib17].

3.4. Preanalytical biobank protocol {#sec3.4}
-----------------------------------

From 2001 to 2013, the only change in our biobank collection protocol was the type of tube used for sample storage, which did not affect biomarker concentrations: values for Sarstedt 1.5/2.0 mL versus Brand 0.5 mL tubes were (median + interquartile range) 504 (158) versus 541 (161) pg/mL for Aβ~1--42~, 788 (525) versus 747 (422) pg/mL for T-tau, and 84 (49) versus 80 (40) pg/mL for P-tau (all *n*.*s*.).

4. Discussion {#sec4}
=============

Our study shows that storage time up to 12 years does not significantly affect the levels of CSF biomarkers Aβ~1--42~, T-tau, and P-tau. Our novel approach was to measure biomarker concentrations in biobanked samples of a homogenous AD cohort using single batches of Aβ~1--42~, T-tau, and P-tau enzyme-linked immunosorbent assays.

We observed differences in Aβ~1--42~ and T-tau levels originally measured in 2001 versus 2013 but did not find significant effects of storage time when biomarkers were measured in the same assay batch. The recently established increase in the cutoff level for Aβ~1--42~ in AD diagnostics [@bib18] and the increase in internal quality control sample concentrations over time (data not shown) [@bib17] support our findings and indicate that batch variation is a factor impeding AD biomarker studies [@bib5]. The development of automated platforms [@bib19] and calibration against reference methods and reference material [@bib20], [@bib21] for biomarker measurement can strongly reduce this variation.

Potential preanalytical processing factors were controlled for as much as possible in this study. To illustrate, the same technician performed the biomarker analyses for this study and for the routine diagnostics since 2009. Moreover, the same routine and biobanking protocols were used throughout the whole period, although we cannot exclude influence of as yet unidentified preanalytical factors. One identified factor in this study was a difference in aliquot volumes between the remeasurements (0.5 mL) and a broader range of volumes for the samples used for routine biomarker measurements at the time of biobank inclusion (between 0.35 and 2.5 mL). However, a potential effect of this difference was not observed as a visual systematic difference between the new and the old biomarker measurements. Another limitation of this study was the large variance in biomarker concentrations in our cohort, which is an inevitable risk in this type of study design, where biomarker concentrations were not part of the selection criteria.

The guidelines for the preanalytical protocol of CSF biomarkers [@bib11] can be updated following this study to include the currently presented stability of CSF biomarkers and the long-term resistance of CSF samples to evaporation [@bib10]. Assay drift over the years is a secondary outcome of the present study and a phenomenon that will be thoroughly addressed in other reports. There are various potential approaches to resolve the consequences of assay drift when using historically measured biomarker levels: (1) remeasurement of the biomarker values in one assay batch, (2) development of statistical models that correct for assay batch as a confounding factor, and (3) more complex statistical models that level out the drift in biomarker concentrations over time. Future studies should carefully consider these solutions.

To conclude, AD biomarker levels prove to be stable on long-term storage. Historically measured Aβ~1--42~ and T-tau concentrations should be applied with caution, because absolute values have increased over time due to analytical assay changes. Statistical correction for an assay batch or remeasurement of the biomarkers provides plausible solutions for this assay drift. Our results encourage the growth of CSF biobanks for dementia biomarker research because historical samples retain their value for AD research over years.Research in Context1.Systematic review: Literature on the topic was identified by searching PubMed for "AD biomarkers" AND "long-term storage" OR "stability." The methods used to assess long-term storage effects in the identified reports were evaluated in detail.2.Interpretation: Our data confirm that the Alzheimer\'s disease (AD) cerebrospinal fluid biomarkers Aβ~1--42~, T-tau, and P-tau are not affected by long-term storage up to 12 years. Stability of these biomarkers has been reported earlier but has not been empirically proven using a design that covers a period of 12 years and precludes effects of batch variation.3.Future directions: The AD biomarkers are stable during biobank storage, which reassures the value of historical patient cohorts for biomarker studies. Long-term stability of other analytes should be assessed. Guidelines should be generated to handle differences in biomarker values caused by batch variation. Potential solutions are (1) remeasurement of the AD biomarkers within one batch and (2) including batch number as a confounding factor in future statistical models.
